Last checked at 22 Apr 2016 10:01
ValiRx Plc
("ValiRx" or "the Company")
COMMUNICATIONS UPDATE
"ValiRx to exhibit at the UK Investor Show"
London, UK, 22nd April 2016: ValiRx Plc (AIM: VAL), a life science company with a focus on cancer diagnostics and therapeutics for personalised medicine, is pleased to announce that the Company will be exhibiting and presenting at the UK Investor Show 2016, which will take place at the Queen Elizabeth II Conference Centre, Broad Sanctuary, Westminster, London, SW1P 3EE on Saturday 30th April 2016.
Dr Satu Vainikka, Chief Executive Officer of ValiRx will make a presentation and a Dragon's Pitch during the day.
Tickets to the event can be found through the following link:
www.ukinvestorshow.com
Representatives of the Company's management team will also be in attendance at the show to welcome existing and potential investors.
About ValiRx Plc
ValiRx Plc is a biopharmaceutical company developing novel technologies and products in oncology therapeutics and diagnostics. The product focus is in the epigenomic analysis and treatment of cancer, but the technologies can be applied to other fields as well, such as neurology and inflammatory diseases.
The Company listed on the Alternative Investment Market ("AIM") of the London Stock Exchange in October 2006.
The Company has a pipeline of other therapeutic drugs, which are currently progressing towards clinical trials. The product focus is in the targeted analysis and treatment of cancer, but the technologies can be applied to other fields as well, such as neurology and inflammatory diseases. It actively manages projects within its portfolio as a trading company. The ValiRx business model spreads the risks of life science technology development by minimizing financial exposure and running a set of projects to defined commercial endpoints. This maximizes returns to shareholders by adding value at the earlier stages where value increases per investment unit are the greatest.
The Company operates through the following divisional companies:
1. ValiPharma is the therapeutics division, with two embedded technologies primarily directed at the treatment of cancers.
2. ValiFinn is the biomarkers and diagnostic development division. ValiRx acquired through its ValiFinn subsidiary, the complimentary TRAC technology to strengthen the portfolio.
3. ValiSeek is a joint venture between ValiRx and Tangent Ltd to develop Val401 in lung cancer and potentially other indications.
*** ENDS ***
For further information on the Company, visit: www.valirx.com:
ValiRx plc | Tel: +44 (0) 20 3008 4416 |
Dr Satu Vainikka, Chief Executive | Tel: +44 (0) 20 3008 4416 |
Tarquin Edwards, Head of Communications. | Tel: +44 (0) 7879 458 364 tarquin.edwards@valirx.com |
Mark Treharne, Corporate Development Manager | Tel: +44 (0) 7736 564 686 mark.treharne@valirx.com |
Northland Capital Partners Limited (Broker) | Tel: +44 (0) 20 7382 1100 |
Patrick Claridge / David Hignell (Corporate Finance) John Howes / Abigail Wayne (Broking) |